Mylan is target of 2 probes, has 3Q loss due to EpiPen fine

Mylan is target of 2 probes, has 3Q loss due to EpiPen fine


The maker of EpiPen emergency allergy injectors, under a microscope for repeatedly jacking up the price of the life-saving device, revealed Wednesday that it's a target of two price-related probes by federal agencies and has had its premises searched. The news, disclosed in a filing with the Securities and Exchange Commission, came after Mylan Inc. reported that it swung to a third-quarter loss, mainly due to a big settlement for overcharging the federal government for the product.



from Biotech News